About the Editors

Editor-in-Chief

Alan D. T. Barrett, PhD
Director, Sealy Center for Vaccine Development
University of Texas Medical Branch, Galveston, Texas, USA

Alan D.T. Barrett obtained his B.S., M.S. and PhD in the area of virology from the University of Warwick, followed by a post-doctoral fellowship in arbovirology at the London School of Hygiene and Tropical Medicine. He is currently Director at the Sealy Center for Vaccine Development and World Health Organization Collaborating Center for Vaccine Research, Evaluating and Training for Emerging Infectious Diseases. He is a Professor in the Departments of Pathology and Microbiology & Immunology at University of Texas, Medical Branch (UTMB). Dr. Barrett is a leading expert in the fields of vaccine development for flavivirus and bunyavirus. His lab is undertaking basic research on the development of vaccines against the flavivirus diseases. This includes West Nile, Japanese encephalitis, yellow fever and dengue. The lab also underatkes and is funded by a number of grants from the NIH. In addition, Dr. Barrett has over 160 publications in the field and is frequently called upon to Chair NIH Special Emphasis panels for biodefense and infectious disease topics.

Associate Editors

Paul A. MacAry, PhD
Director, LSI Immunology Programme & Co-Chair CREATE-HUJ Consortium
National University of Singapore, Singapore

Associate Professor Paul MacAry received his BSc (Hons) in Molecular Genetics from Glasgow University in 1993 and his PhD in Immunology from GKT, University of London in 1998.  He performed post-doctoral researches in the Cambridge University Institute for Medical Research (CIMR) and since 2005 has been an independent investigator in the Department of Microbiology and Immunology program at the National University of Singapore (NUS). The multi-disciplinary research in his laboratory covers the entire spectrum of scientific endeavour, from basic research to industrial applications with an emphasis on antibody biology, immune repertoire mapping and protein engineering applications in infectious diseases. Professor MacAry was a founding member and Meetings Secretary for the Singaporean Society of Immunology (SSI) - Singapore’s first international learned society - and the founding scientist for two biotechnology companies, BSCR LTD founded in Cambridge in 2004 and Antibody Cradle LTD founded in Singapore in 2012.

Veronika von Messling, Dr. med. vet.
Director of the Veterinary Medicine
Paul-Ehrlich-Institut, Langen, Germany

Prof  Dr. Veronika von Messling is Director of the Veterinary Medicine Division at the Paul-Ehrlich Institute, the German Federal Institute of Vaccines and Biomedicines, in Langen, Germany.  She obtained her veterinary degree and her doctorate degree in veterinary virology from the Veterinary School Hannover, Germany.  After postdoctoral training at Mayo Clinic in Rochester, MN, she was an Assistant Professor at INRS-Institut Armand-Frappier in Laval, QC, and then Associate Professor at Duke-NUS Medical School, Singapore. Her research interest lies in characterizing the pathogenesis of respiratory viruses to develop novel prophylactic and therapeutic strategies. Dr. von Messling has been awarded various awards and prizes such as the Chercheur-boursier senior Award, FRSQ, (2011), and the Löffler-Frosch Prize, German Society of Virology (2011). She is also a member of various societies such as the European Society of Virology, Canadian Society of Microbiology and Deutsche virologische Gesellschaft.

Pei-Yong Shi, PhD
I.H. Kempner Professor of Human Genetics, Department of Biochemistry and Molecular Biology
University of Texas Medical Branch, Galveston, Texas, USA

Along with his post at UTMB, Pei-Yong Shi serves as adjunct Professor of Emerging Infectious Diseases at the Duke-NUS Graduate Medical School in Singapore and Honorary Professor at the Wuhan Institute of Virology, Chinese Academy of Sciences. He studies flavivirus replication and develops antivirals and vaccines. He received his PhD in virology in 1996 from Georgia State University. After postdoctoral training at Yale, he joined Bristol-Myers Squibb as a Principal Scientist to develop HIV and HCV therapeutics from 1998-2000. He then moved to the Wadsworth Center, New York State Department of Health, to study West Nile virus. From 2008 to 2015, he served as Executive Director to lead drug discovery at Novartis Institute for Tropical Diseases. At UTMB, his group developed the first infectious clone of the epidemic strain of West Nile virus, discovered two cap methylation activities of flavivirus NS5 protein, identified essential RNA elements for flavivirus replication, established various platforms for flavivirus vaccine and drug discovery, and pioneered therapeutics development for dengue virus.

Richard Titball, DsC, PhD
Professor of Molecular Microbiology
University of Exeter, Exeter, United Kingdom

Richard Titball is Professor of Molecular Microbiology at the University of Exeter, having moved from the Defence Science and Technology Laboratory (Dstl) at Porton Down in 2007, where he was a Senior Fellow. Prof. Titball worked extensively on a range of bacterial pathogens including Burkholderia pseudomallei, Francisella tularensis, Yersinia pestis, Campylobacter jejuni and Clostridium perfringens. His past work has provided new insight into the molecular architectures and mode of action of C. perfringens toxins and he led initiatives to sequence the first genomes of a range of candidate biothreat agents. Prof. Titball’s work also resulted in the development of vaccines against plague and C. perfringens toxins which have been trialled in humans and in animals, respectively.  His principal interests now lie with understanding the molecular basis of disease caused by B. pseudomallei and C. jejuni. He continues to have a strong interest in the development of vaccines against B. pseudomallei and C. perfringens toxins. This work includes understanding the role that vaccines might have in controlling chronic and persistent disease and the use of novel vaccine delivery systems.

David H. Walker, MD, Professor
Department of Pathology
University of Texas Medical Branch, Galveston, Texas, USA

David Walker is the Director of the Center for Biodefense and Emerging Infectious Diseases, and Professor and former Chairman of the Department of Pathology at the University of Texas Medical Branch at Galveston. He receieved his M.D. from Vanderbilt University, and then later served as a Research and Clinical Fellow at Harvard University School of Medicine. Dr. Walker’s research has elucidated mechanisms of immunity to Rickettsia and Ehrlichia, developed animal models for investigating rickettsioses and ehrlichioses, and contributed to elucidating the pathology and pathophysiology of Lassa fever, Rocky Mountain spotted fever, Mediterranean spotted fever, and human monocytotropic ehrlichiosis. Among emerging infections, he contributed to the discovery, characterization, and/or epidemiology of Anaplasma phagocytophilum (human granulocytotropic anaplasmosis), Rickettsia japonica (Japanese spotted fever), R. felis (flea-borne spotted fever), and E. chaffeensis (human monocytotropic ehrlichiosis).